Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas
South Asia’s largest exhibition for pharma brought together over 50,000 visitors from across the globe
40,000 visitors and representatives of more than 80 countries set to visit the show
Joint Drugs Controller (India) Dr PBN Prasad shared his views about working during harsh COVID-19 pandemic days
The show will be a part of the India Pharma Week, a marquee celebration catering to every need of the pharma community attendees
The company sees the business reaching $100mn
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Subscribe To Our Newsletter & Stay Updated
